U.S. Retail Distributors Stock News

Pennant Group (PNTG) just picked up fresh Wall Street attention, with William Blair’s Ryan Daniels initiating coverage at a buy rating, a move that often nudges new investors to revisit the story. See our latest analysis for Pennant Group. The upbeat call lands after a strong run. Pennant’s roughly 17% 1 month share price return and a powerful 3 year total shareholder return signal that momentum is firmly building, despite a still muted 1 year total shareholder return. If this kind of renewed...

In late November, Vistra completed its purchase of seven natural gas plants from Lotus Infrastructure Partners, announced plans for two new gas units in West Texas, and received an S&P Global credit upgrade to BBB-, reflecting improved balance sheet strength after a nuclear power sales deal and expanded generation footprint. KeyBanc’s recent initiation of coverage with a positive view on Vistra’s scale, diversified generation mix, and cash flow highlights how the company’s growing mix of...

Digital Asset, together with a consortium of major financial institutions including Virtu Financial, recently completed a second set of onchain U.S. Treasury financing transactions on the Canton Network, progressing efforts to build always-on capital markets infrastructure. This collaboration highlights Virtu’s role in advancing onchain liquidity and real-time collateral reuse, aligning its trading expertise with emerging blockchain-based market structures. We’ll now explore how Virtu’s...

PTC Therapeutics (PTCT) has quietly become one of this year’s stronger rare disease stories, with the stock climbing about 64% year to date and nearly doubling over the past 3 years. See our latest analysis for PTC Therapeutics. That kind of move is not just noise, with a 23.49% 3 month share price return and a 95.95% 3 year total shareholder return suggesting momentum in the rare disease story is still building. If PTCT’s run has you rethinking your exposure to healthcare innovators, it...

Ross Stores (ROST) just posted another quarter of solid momentum, with higher sales, 90 new stores, and a new distribution center that together signal management is still pressing its long term expansion strategy. See our latest analysis for Ross Stores. The strong operations story seems to be feeding straight into sentiment, with roughly 12% 1 month share price return and a 66% 3 year total shareholder return suggesting momentum is still building rather than fading. If Ross’s run has you...

SELLAS Life Sciences Group recently reported Phase 2 data showing that its CDK9 inhibitor SLS009, combined with azacitidine and venetoclax, achieved a 46% overall response rate and extended median survival in heavily pretreated relapsed or refractory AML-MR patients, with no dose-limiting toxicities or treatment-related deaths observed. An especially important finding was the strong activity in patients with high-risk ASXL1 and TP53 mutations and in those with only one prior line of therapy,...

Everus Construction Group (ECG) just saw Director Helena Hernandez add 250 shares to her stake, extending a year long streak of insider buying with no selling, a pattern investors tend to watch closely. See our latest analysis for Everus Construction Group. That steady drumbeat of insider buying comes as Everus Construction Group’s share price has climbed to $101.21, with a strong 90 day share price return of 28.65 percent and a 1 year total shareholder return of 47.11 percent, pointing to...

Trade Desk (TTD) is back in the spotlight after a steep share price slide, with investors trying to reconcile short term pressure from higher costs and tougher competition with its long term connected TV and retail media ambitions. See our latest analysis for Trade Desk. The latest move takes Trade Desk’s 30 day share price return to a steep negative 16.24%, compounding a year to date share price loss of 68.56% and a 12 month total shareholder return of negative 72.28%. This indicates clearly...

McCormick (MKC) has quietly underperformed the broader market over the past year, even as its revenue and profit kept growing. That gap between fundamentals and share price is exactly what makes the stock interesting now. See our latest analysis for McCormick. After sliding earlier in the year, McCormick’s recent 1 week share price return of 3.94 percent suggests sentiment may be stabilizing, even though the 1 year total shareholder return remains a weak negative. If that shift in momentum...

If you are wondering whether Exact Sciences at around $101 a share is still a smart buy or if the easy money has already been made, you are not alone and that is exactly what we are going to unpack. The stock has climbed 50.2% over the last month and is up 78.1% year to date, while still carrying a 127.2% gain over 3 years despite being 25.5% lower than 5 years ago, a rollercoaster that clearly signals shifting views on its growth potential and risk. Much of that renewed enthusiasm has been...

Ciena (CIEN) just put some numbers behind the excitement, issuing upbeat revenue guidance for the first quarter and full fiscal 2026 that leans on rising Cloud and AI network demand. See our latest analysis for Ciena. The upbeat guidance has supercharged sentiment, with Ciena’s share price jumping 9.25% in the last session and delivering a 90 day share price return of 84.62%, while its 1 year total shareholder return of 186.76% and 3 year total shareholder return of 399.42% show that this...

Rhythm Pharmaceuticals recently announced positive preliminary data from an exploratory Phase 2 trial of setmelanotide in Prader-Willi syndrome, reporting reductions in BMI and hyperphagia and indicating plans to advance to a Phase 3 registrational study. The company is also extending its Prader-Willi program with a Phase 1, Part D study of weekly MC4R agonist RM-718, signaling a broader, multi-asset approach to this rare obesity indication. Next, we’ll examine how setmelanotide’s...

Warner Music Group (WMG) just handed the creative keys to longtime A&R heavyweight Craig Kallman, naming him Chief Music Officer and tasking him with shaping artist development across the entire global roster. See our latest analysis for Warner Music Group. The appointment of Kallman as Chief Music Officer lands at a tricky market moment, with Warner Music Group’s 1 month share price return of -8.45 percent and 1 year total shareholder return of -12.85 percent pointing to fading momentum...

AngloGold Ashanti (NYSE:AU) heads into its Resourcing Tomorrow conference appearance with a timely backdrop, a 20% jump in gold production and reaffirmed multi year output guidance that puts the Sukari acquisition firmly in focus for investors. See our latest analysis for AngloGold Ashanti. That production jump and confident guidance seem to be feeding into sentiment, with the share price up 7.75% over the past month and a powerful 251.27% year to date share price return. The 3 year total...

Ferrari (RACE) has quietly slipped about 13% over the past month and roughly 23% in the past 3 months, even as revenue and net income keep growing at mid single digit rates. See our latest analysis for Ferrari. Zooming out, the recent 1 month and 3 month share price pullback contrasts with a still strong 3 year total shareholder return. This suggests momentum has cooled, but the longer term Ferrari story remains intact. If Ferrari’s recent slide has you reassessing the auto space, it could be...

Burlington Stores (BURL) is getting fresh attention after management nudged its 2026 expansion plans higher, lifting the target to 110 net new stores, supported by 45 leases picked up from Joann Fabrics’ bankruptcy. See our latest analysis for Burlington Stores. The expansion news lands at a mixed moment for the stock, with a recent 7 day share price return of 4.9% helping to offset a weaker year to date share price return and a modestly negative 1 year total shareholder return. At the same...

In recent days, Deutsche Bank downgraded Norfolk Southern to a Hold rating, signaling increased caution around the railroad operator’s outlook and operations. At the same time, a meaningful reduction in short interest suggests some bearish investors have scaled back their positions, hinting at a shift in market sentiment. We’ll now examine how Deutsche Bank’s downgrade may influence Norfolk Southern’s existing investment narrative and future risk‑reward balance. Uncover the next big thing...

Earlier this month, several analysts upgraded Lear Corporation after management indicated fourth-quarter 2025 results should land at the upper end of guidance and flagged a return to positive revenue and earnings growth next year, supported by reshoring, deeper Chinese OEM exposure and automation-led cost savings. At the same time, one major bank downgraded its rating, so the overall picture now reflects growing optimism around Lear’s operational improvements while still highlighting...

Kewaunee Scientific (KEQU) has just turned in a mixed Q2 2026 scorecard, posting revenue of about $70.1 million and EPS of $0.85 as profitability continues to reflect a narrower net margin profile than a year ago. The company has seen quarterly revenue move from $47.8 million in Q2 2025 to $70.1 million in Q2 2026, while quarterly EPS has swung between $0.47 and $1.70 over the same stretch, underscoring how choppy earnings have become as margins compressed from last year’s levels. See our...

Earlier this month, The GEO Group Inc. announced that long‑time Senior Vice President, Legal Services, General Counsel, and Corporate Secretary Joe Negron will retire effective December 31, 2025, after serving in his current roles since 2019, and will remain as a consultant on legal, regulatory, and compliance matters for two years starting January 1, 2026. This transition keeps Negron’s institutional and regulatory expertise tied to GEO as investor attention increasingly centers on the...

Praxis Precision Medicines (PRAX) just checked several big regulatory boxes, with the FDA signaling a path toward New Drug Applications for relutrigine and ulixacaltamide while elsunersen’s EMBRAVE3 trial shifts into a faster single arm design. See our latest analysis for Praxis Precision Medicines. Those rapid fire regulatory wins have gone hand in hand with a powerful rerating, with Praxis posting a roughly 609% 3 month share price return and a 627% 3 year total shareholder return,...

T. Rowe Price Group recently reported that its assets under management stood at US$1.79 trillion at the end of November, alongside US$8.0 billion in net client outflows for the month, while also reshaping operations with a new Technology, Data, and Operations function. These sizable outflows, combined with organizational changes and ongoing investment in technology and global distribution, highlight the tension between the firm’s strong retirement franchise and current pressure on organic...

Repligen (RGEN) is back in focus after fresh coverage spotlighted a growing disconnect between its acquisition driven expansion and softer organic revenue growth, along with a clear slide in operating margins. See our latest analysis for Repligen. The latest note seems to have cooled sentiment a little, with a modest pullback in the 7 day share price return after a strong 90 day share price rally and only lukewarm 1 year total shareholder return. This hints that momentum is still rebuilding...

Daktronics (DAKT) just stacked several important updates into one quarter, combining solid Q2 sales and order growth with a deeper product backlog, a new CEO on deck, and expanded manufacturing capacity. See our latest analysis for Daktronics. That operational momentum is starting to show up in the market too, with the share price at around $20.51 and a robust year to date share price return of roughly 23%, building on a remarkable three year total shareholder return above 700%. If Daktronics...